Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.63 -4.2%	$0.71	$0.49 ▼ $2.75	$58.77M	1.88	272,468 shs	190,117 shs
IMAB I-Mab	$2.34 -3.3%	$1.56	$0.60 ▼ $3.08	$197.62M	1.39	388,796 shs	453,641 shs
PRQR ProQR Therapeutics	$2.01 -1.5%	$1.77	$1.07 ▼ $4.62	$214.63M	0.36	655,716 shs	380,002 shs
SOPH SOPHiA GENETICS	$3.29 +6.1%	$3.02	$2.58 ▼ $4.92	$206.73M	1	58,794 shs	60,667 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	-4.23%	+8.98%	+7.08%	-7.86%	-65.33%
IMAB I-Mab	-3.31%	-1.27%	+80.00%	+200.66%	+44.44%
PRQR ProQR Therapeutics	-1.47%	-0.99%	+19.64%	+46.72%	+21.82%
SOPH SOPHiA GENETICS	+6.13%	+4.44%	+10.40%	0.00%	-29.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTX Context Therapeutics	3.4541 of 5 stars	3.6	4.0	2.6	1.7	1.3
IMAB I-Mab	3.1425 of 5 stars	3.7	3.0	3.3	1.7	0.6
PRQR ProQR Therapeutics	2.1074 of 5 stars	3.6	3.0	3.1	0.0	0.0
SOPH SOPHiA GENETICS	2.635 of 5 stars	3.3	5.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	3.17	Buy	$5.50	776.49% Upside
IMAB I-Mab	3.33	Buy	$6.00	156.41% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	298.01% Upside
SOPH SOPHiA GENETICS	2.67	Moderate Buy	$7.00	112.77% Upside

Current Analyst Ratings Breakdown

Latest CNTX, IMAB, PRQR, and SOPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/26/2025	CNTX Context Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$4.50 ➝ $4.00
5/13/2025	PRQR ProQR Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $9.00
5/8/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/29/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/29/2025	CNTX Context Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/29/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$8.00
4/29/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
4/21/2025	CNTX Context Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$1.27 per share	N/A
IMAB I-Mab	$3.89M	49.12	N/A	N/A	$2.47 per share	0.95
PRQR ProQR Therapeutics	$20.46M	10.34	N/A	N/A	$0.91 per share	2.21
SOPH SOPHiA GENETICS	$65.17M	3.37	N/A	N/A	$1.48 per share	2.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$26.73M	-$0.31	N/A	N/A	N/A	N/A	-29.78%	-29.08%	8/6/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.81%	-18.63%	8/27/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.35	N/A	N/A	N/A	-157.04%	-53.49%	-22.07%	8/4/2025 (Estimated)
SOPH SOPHiA GENETICS	-$62.49M	-$1.00	N/A	N/A	N/A	-98.51%	-63.47%	-40.06%	8/5/2025 (Estimated)

Latest CNTX, IMAB, PRQR, and SOPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CNTX Context Therapeutics	-$0.05	-$0.05	N/A	-$0.05	N/A	N/A
5/8/2025	Q1 2025	PRQR ProQR Therapeutics	-$0.09	-$0.1082	-$0.0182	-$0.11	$4.90 million	$4.89 million
5/6/2025	Q1 2025	SOPH SOPHiA GENETICS	-$0.21	-$0.26	-$0.05	-$0.26	$16.76 million	$17.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	48.81	48.81
IMAB I-Mab	N/A	22.35	22.35
PRQR ProQR Therapeutics	N/A	4.10	4.10
SOPH SOPHiA GENETICS	0.16	3.11	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
IMAB I-Mab	38.38%
PRQR ProQR Therapeutics	32.65%
SOPH SOPHiA GENETICS	31.59%

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	3.04%
IMAB I-Mab	22.10%
PRQR ProQR Therapeutics	8.40%
SOPH SOPHiA GENETICS	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	7	89.70 million	86.98 million	Not Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable
SOPH SOPHiA GENETICS	520	66.69 million	63.43 million	Not Optionable

CNTX, IMAB, PRQR, and SOPH Headlines

Recent News About These Companies

Sophia Genetics launches podcast to decode data- and AI-driven medical innovation

June 27, 2025 | fiercepharma.comF

An end to an era: Supreme Court won't review IVF mixup ruling

June 26, 2025 | israelnationalnews.comI

Enough hype about AI in health—let’s talk about results

June 12, 2025 | fastcompany.comF

M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care

June 3, 2025 | zawya.comZ

M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care

June 3, 2025 | msn.com

M42, partners launch liquid biopsy testing in UAE

June 3, 2025 | tradearabia.comT

The Multimodal Imperative: How AI-Driven Technology is Driving Impactful Changes

June 2, 2025 | fiercepharma.comF

'An unusual precedent': Baby Sophia's genetic parents demand new Supreme Court hearing

May 28, 2025 | israelnationalnews.comI

High Court grants custody of IVF baby to adoptive, not biological parents

May 12, 2025 | msn.com

SOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 12, 2025 | uk.finance.yahoo.com

Supreme Court: IVF mixup baby to remain with birth parents

May 12, 2025 | israelnationalnews.comI

Supreme Court upholds decision to keep IVF child with birth mother following embryo mix-up

May 12, 2025 | msn.com

Supreme Court rules birth parents of child born in IVF mix-up are legal parents

May 12, 2025 | msn.com

The Sophia Case: When Parenthood Isn’t Just About Genetics

May 10, 2025 | blogs.timesofisrael.comB

SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Sophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ...

May 7, 2025 | finance.yahoo.com

SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

SOPHiA GENETICS Reports First Quarter 2025 Results

May 6, 2025 | prnewswire.com

SOPHiA GENETICS expands AstraZeneca liquid biopsy test

April 30, 2025 | investing.com

SOPHiA GENETICS Expands AstraZeneca Partnership to Advance Liquid Biopsy Worldwide

April 29, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX, IMAB, PRQR, and SOPH Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.63 -0.03 (-4.23%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$0.64 +0.01 (+1.83%)

As of 07/1/2025 07:53 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

I-Mab NASDAQ:IMAB

$2.34 -0.08 (-3.31%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$2.29 -0.05 (-2.14%)

As of 07/1/2025 07:48 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

ProQR Therapeutics NASDAQ:PRQR

$2.01 -0.03 (-1.47%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$1.98 -0.02 (-1.24%)

As of 07/1/2025 07:36 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

SOPHiA GENETICS NASDAQ:SOPH

$3.29 +0.19 (+6.13%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$3.28 -0.01 (-0.33%)

As of 07/1/2025 04:25 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time